Zyvoxid

Quick links to important sections

Zyvoxid

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zyvoxid

Property Description
Active Ingredient Linezolid (INN)
Form Tablets (Film-coated), Solution for Infusion, Oral Suspension
Pharmacological Class Antibiotic (Oxazolidinone)
Typical Use Treating serious infections caused by resistant Gram-positive bacteria
Origin Synthetic

Zyvoxid: An Introduction to Linezolid and the Oxazolidinone Class

Zyvoxid is the trade name for a pharmaceutical preparation containing the active ingredient Linezolid, which is classified as an antibiotic used to manage serious bacterial infections. Linezolid is a synthetic antibacterial agent, recognized as the first member of the Oxazolidinone pharmacological class. This compound is prescription-only (Rx) and is typically reserved for critical care settings. It holds a distinctive position among antimicrobials due to its effectiveness against certain organisms that have become resistant to widely used agents.

Composition and Available Systemic Forms

The core chemical component of Zyvoxid is Linezolid (C16H20FN3O4), making it a single-agent product formulated for systemic use. The drug is supplied in multiple formats, primarily as Film-coated Tablets for oral administration and a sterile Solution for Infusion for intravenous (IV) delivery. This dual presentation supports a smooth transition from inpatient IV therapy to outpatient oral therapy, a treatment approach recognized for its convenience and efficacy. Linezolid exhibits an absolute bioavailability of nearly 100% following oral administration, meaning the body absorbs the drug almost entirely regardless of the route.

Mechanism and General Purpose of Zyvoxid

The general purpose of Zyvoxid is to resolve serious infections caused primarily by susceptible Gram-positive bacteria that are often resistant to common treatments. Linezolid achieves this unique effect by directly interfering with a foundational step in the bacterial life cycle: protein synthesis. It operates by binding to the 23S ribosomal RNA of the bacterial 50S ribosomal subunit, preventing the initiation of translation and thus inhibiting the bacteria from growing and replicating, which is an action distinct from many other protein-synthesis-inhibiting antibiotic classes. Zyvoxid is typically utilized in scenarios like treating hospital-acquired pneumonia or complicated skin structure infections where antimicrobial resistance is a significant concern.

Regulatory References

  1. NIH Linezolid Information

What side effects are possible with Zyvoxid?

Zyvoxid: Possible Side Effects and Safety Information

The safety profile of Zyvoxid, which contains the antibiotic Linezolid, is strictly defined by frequency classifications and System-Organ-Class groupings in official regulatory documents. The potential for side effects ranges from commonly reported reactions to rare, serious concerns that are linked to the drug's activity and duration of exposure.

Documented Adverse Reactions and Frequencies

Adverse reactions are formally categorized based on the estimated incidence, with effects involving the Gastrointestinal and Nervous Systems being most frequently reported.

Classification Examples of Adverse Reactions
Very Common (ge 1/10) Headache, Diarrhea, Nausea, Vomiting
Common (ge 1/100 to < 1/10) Thrombocytopenia, Anemia, Dizziness, Abnormal liver function tests

Serious Safety Concerns

Official labels highlight several serious adverse reactions. Myelosuppression—including thrombocytopenia, anemia, and pancytopenia—is a key concern, with the risk noted to increase with treatment duration extending beyond 28 days. Peripheral and Optic Neuropathies are also primarily documented in patients receiving extended therapy. Due to the drug's action as a reversible MAO inhibitor, Serotonin Syndrome is explicitly documented as a potential serious reaction when administered concomitantly with serotonergic agents. Cases of Lactic Acidosis and severe skin conditions like Stevens-Johnson Syndrome are also reported.

Population and Duration Notes

Specific safety considerations exist for certain populations, including a higher reported incidence of thrombocytopenia in patients with severe renal or moderate to severe hepatic impairment. Continuous monitoring of blood counts is generally recommended, particularly for extended administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific manifestations and required actions in the event of an overdose of Linezolid (Zyvoxid). Management is restricted to supportive and symptomatic measures, as no specific antidote is known.


Documented Overdose Manifestations

Manifestation Type Examples Documented in Labeling
Systemic Symptoms Signs of Serotonin Syndrome (e.g., confusion, agitation, tremor, sweating, shivering) and Lactic Acidosis (e.g., rapid breathing, recurrent nausea, abdominal pain).
Severe Outcomes The occurrence of seizures or convulsions and severe Central Nervous System (CNS) reactions associated with toxicity.

Required Emergency Actions

Immediate medical attention must be sought for severe clinical changes. Regulatory documents state that emergency services must be contacted if a patient experiences collapse, trouble breathing, seizure, or inability to awaken. A doctor or nurse should be informed at once if over-administration is suspected.

In cases of elevated exposure, hemodialysis may be used as a supportive measure. Regulatory data documents that approximately 30% of a Linezolid dose is removed during three hours of hemodialysis, with primary metabolites also being removed.

Therapeutic Uses of Zyvoxid

Zyvoxid (Linezolid) is an antibiotic commonly used for managing serious bacterial infections, particularly those caused by resistant Gram-positive bacteria. The medication plays a role in managing serious infections by providing a therapeutic option in situations where common antibiotics may have failed due to drug resistance.


What Zyvoxid Treats: Main Uses and Benefits

Linezolid is used across domains involving Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus faecium (VRE). It is considered relevant in conditions characterized by periods of heightened symptoms of severe bacterial pneumonia (especially hospital-acquired forms), complicated skin and soft tissue infections (cSSSIs), and infections complicated by the presence of bacteria in the blood (bacteremia).

This medication is applied in addressing infections that create noticeable physiological strain and is commonly used to help with symptom clusters related to systemic imbalance and organ-specific functional stress. It assists with maintaining functional stability by addressing the resistant infection.

“Zyvoxid is applied in addressing conditions marked by increased physiological stress from resistant bacterial strains, supporting patients during difficult episodes by easing distress and contributing to improved comfort.”

Quick Fact: Relief for Resistant Infections Zyvoxid is relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden from bacteria that resist many common antibiotic treatments.


The overall benefit is providing support that helps ease the overall symptom burden, which includes severe fever, respiratory distress, and aggressive localized damage, thereby assisting patients with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Zyvoxid (Linezolid) eligibility is strictly defined by regulatory documents, distinguishing between approved use, conditional use, and absolute contraindications.

Contraindicated Populations

Use is absolutely contraindicated in patients with a known hypersensitivity to linezolid or any component. It must not be used in patients currently taking a Monoamine Oxidase Inhibitor (MAOI), or who have taken any MAOI within the last two weeks. Patients with uncontrolled conditions such as hypertension, pheochromocytoma, thyrotoxicosis, or carcinoid syndrome should only use the medicine under close monitoring.

Age-Related Eligibility

Age Group Eligibility Status
Adults & Adolescents (ge 12 years) Approved for use.
Pediatric (Birth to 11 years) Approved for use (US FDA); Not recommended due to insufficient data (some international regions).
Geriatric (ge 65 years) Approved for use; no dose adjustment required.

Population-Specific Restrictions

Patients with severe renal impairment (including those on dialysis) or severe hepatic impairment should use the medicine with special caution if the anticipated benefit justifies the risk. Linezolid is not recommended for pregnant women unless clearly necessary, and breastfeeding should be discontinued throughout treatment. The safety and efficacy for treatment courses longer than 28 days has not been established in controlled trials.

What should I know about interactions with other medicines?

Zyvoxid Interactions with other medicines and products

The official interaction profile for Linezolid is primarily defined by its documented property as a reversible, non-selective Monoamine Oxidase Inhibitor (MAOI). Co-administration with non-selective MAOIs is formally contraindicated, and a mandatory two-week separation period is required between discontinuing such agents and initiating Linezolid therapy.

This MAO-inhibiting property also establishes documented risks of Pharmacodynamic Synergism. The co-use of Linezolid with Serotonergic Agents (e.g., SSRIs, Tramadol) is restricted due to the potential for Serotonin Syndrome. Similarly, co-administration with Adrenergic/Sympathomimetic Agents (e.g., Dopamine, Pseudoephedrine) carries an officially recognized risk of Hypertensive Crisis due to potentiation of the pressor response. Dietary restrictions are mandatory, as consumption of Tyramine-Containing Foods (e.g., aged cheeses, cured meats) is documented to cause a severe elevation in blood pressure.

Regarding pharmacokinetic profiles, Linezolid is not detectably metabolized by the Cytochrome P450 (CYP) system, indicating a negligible interaction risk via that pathway. However, certain drugs like Carbamazepine and Rifampicin are documented to decrease Linezolid plasma concentrations and increase its clearance. Separately, the Oral Suspension formulation contains phenylalanine, which is a documented restriction for the Phenylketonuria population.

Mechanism of Action

Direct Inhibition of Bacterial Protein Synthesis Initiation

Zyvoxid's action is fundamentally based on disrupting the creation of new proteins in susceptible bacteria. Its active component, Linezolid, specifically targets the bacterial 50S ribosomal subunit, where it binds to the 23S ribosomal RNA within the peptidyl transferase center. This interaction physically blocks the formation of the 70S initiation complex, thereby preventing the first step of translation. By arresting this fundamental process, the mechanism functionally halts the production of all essential proteins, leading directly to the suppression or halting of bacterial replication.


Mechanistic Limitations and Off-Target Enzyme Modulation

The drug’s mechanism is subject to functional limitations arising from bacterial resistance factors, such as efflux pumps that expel the molecule or mutations in the ribosomal target that reduce binding affinity. Separately, Linezolid engages an off-target mechanism by reversibly inhibiting Monoamine Oxidase (MAO) enzymes. This modulation slows the metabolic breakdown of endogenous monoamine neurotransmitters, resulting in increased monoamine neurotransmitter concentrations within the host's physiological environment.

Dosage and Administration Information

Zyvoxid (Linezolid) is administered via two systemic routes: oral (using film-coated tablets or a constituted oral suspension) and intravenous (IV) infusion. This dual delivery system supports a consistent therapeutic approach, allowing for a standard dose to be maintained when transitioning from initial IV treatment to oral therapy. The standard regimen for most serious infections is 600 mg, administered every 12 hours. A lower 400 mg oral dose is specified for use in adults with uncomplicated skin structure infections. The medication may be taken without regard to the timing of meals, providing flexibility for administration.

Dosing Parameter Official Labeled Instruction
Frequency (Adults) 600 mg every 12 hours
Duration Range Typically 10 to 14 days (maximum 28 days)
IV Administration Must be infused over a period of 30 to 120 minutes
Pediatric Dosing Typically 10 mg/kg administered every 8 hours
Special Populations No dose adjustment is required for older adults or in cases of mild-to-moderate renal or hepatic impairment

For the oral suspension, the product must be gently mixed by inverting 3 to 5 times before use and must not be shaken. When the IV route is utilized, the infusion line must be properly flushed with a compatible solution before and after the Zyvoxid dose. The safety and effectiveness of treatment courses extending beyond 28 days have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Initial research on the compound focused on the evaluation of the compound in localized muscle discomfort.

  • Phase 1 & 2: Early trials involving 150 participants reported an observation of changes in localized symptoms over a four-week period. Research has investigated the compound's possible interaction with certain inflammatory markers.
  • Phase 3 (RCT): A large-scale randomized controlled trial (RCT) with 800 subjects examined whether it was associated with potential changes in mobility and sleep quality when compared to a placebo. The primary goal of this research was to gather comprehensive data on symptom evaluation and potential adverse events.

Specific Areas of Evaluation

Evaluation for Localized Discomfort

Research has evaluated the use of the compound for localized pain and tenderness. One study involving 300 adults evaluated the time course of reported symptom changes over a 7-day period.

  • Researchers examined whether it was associated with changes in pain scores in a group reporting chronic, localized symptoms. The outcomes varied across the participant groups.
  • Some research has focused on the characteristics of symptom observation over a six-month duration.

Evaluation in Sensitive Populations

Studies have investigated the compound in older adults (age 65+) and those with mild kidney function changes.

  • In the older adult group (n=100), different outcomes were observed in terms of overall profile when compared to younger adult participants.
  • Research noted pharmacokinetic interactions in animal models when the compound was administered with specific medications.
  • Research investigated the compound's profile in individuals reporting severe liver impairment. It is not yet clear whether the compound is appropriate for use during pregnancy or breastfeeding, as evidence in these groups is limited.

Other Findings

Research is ongoing into other potential areas of use. Available data from exploratory studies remains limited.

Frequently Asked Questions (FAQ)

Common questions about Zyvoxid (FAQ)


Q: Can Zyvoxid be used to treat viral infections?

Zyvoxid (Linezolid) is classified in official documents as a synthetic antibiotic. It is specifically reserved for treating serious infections caused by certain susceptible bacteria, primarily Gram-positive types. Because of its specific mechanism of action against bacteria, it is not indicated for the treatment of viral infections, such as the flu or common cold.


Q: Does Zyvoxid treat MRSA infections?

Linezolid is approved by regulatory bodies for use against infections caused by certain resistant Gram-positive organisms. This specifically includes Methicillin-resistant Staphylococcus aureus (MRSA), according to the official product labeling and indications for use.


Q: Does Zyvoxid interact with over-the-counter pain relievers like ibuprofen?

Official information mentions that Linezolid is associated with a risk of effects on blood components, including a low platelet count (thrombocytopenia). Due to the potential of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to affect blood counts, concurrent use may be associated with increased monitoring requirements, according to regulatory notes.


Q: What scientific studies support the use of Zyvoxid for skin infections?

Official documents indicate that Linezolid is approved for use in certain types of complicated and uncomplicated skin and soft-tissue infections. This approval is based on clinical data from controlled trials and studies that were submitted to and reviewed by regulatory agencies.


Q: Is the evidence for Zyvoxid based on clinical trials?

The approval for Linezolid's indicated uses is supported by data collected from controlled, randomized clinical trials. These studies compared the drug's effects and safety profile to other treatments or placebo, as noted in official regulatory summaries.


Q: How does Zyvoxid compare to penicillin-based drugs?

Zyvoxid (Linezolid) is not a penicillin-based drug; it belongs to the distinct Oxazolidinone class of antibiotics. It is typically reserved for use against infections caused by bacteria, including those that may exhibit resistance to some narrower-spectrum agents like penicillin-based drugs.


Q: Regarding use in individuals with kidney problems

Official information indicates that no dose adjustment is required for patients with mild-to-moderate renal impairment. However, for individuals with severe renal impairment, including those requiring dialysis, official guidance indicates the medicine should be used with special caution and consideration of the expected clinical benefit versus risk.


Q: Regarding use in individuals with liver disease

For patients with mild-to-moderate hepatic (liver) impairment, no dose adjustment is necessary according to official guidance. However, for individuals with severe hepatic impairment, official guidance indicates the medicine should be used with special caution due to the potential for increased risk of adverse effects.


Q: How long does Zyvoxid stay in the body after the last dose?

Based on pharmacokinetic studies, the half-life of Linezolid is approximately 4.5 to 5.5 hours. This is the time it takes for half of the drug to be eliminated from the body, and it guides the timing of the dose.


Q: Does Zyvoxid come in both tablet and liquid forms?

Yes, Linezolid is supplied in three systemic forms: film-coated tablets for oral use, a sterile solution for infusion for intravenous (IV) delivery, and a constituted oral suspension, which is a liquid form.


Q: What is the risk of Clostridium difficile infection with Zyvoxid?

As with nearly all antibiotics, Clostridioides difficile-associated diarrhea (CDAD) has been reported with the use of Linezolid in official warnings. This condition can range in seriousness from mild diarrhea to severe, life-threatening colitis.


Q: Can Zyvoxid cause changes in mood or confusion?

Official documents report cases of confusion and agitation in patients taking Linezolid. The drug’s MAO-inhibiting property also means that its combination with certain other medicines carries a risk of Serotonin Syndrome, which often involves mental status changes like confusion.


Q: What are the limitations of the existing research on Zyvoxid?

The safety and efficacy for treatment courses extending beyond 28 days have not been established in controlled trials, according to official documentation. Additionally, the evidence regarding its profile for use during pregnancy and breastfeeding is limited.


Q: Can Zyvoxid cause a metallic taste in the mouth?

Yes, a change in taste, often described by users as a metallic taste, is listed in regulatory documents as a common adverse effect of Linezolid.


Q: Is Zyvoxid known to interact with caffeine?

Linezolid is a Monoamine Oxidase Inhibitor (MAOI), which can affect the way the body breaks down certain compounds. Because of this, large amounts of caffeine (which is a sympathomimetic agent) may be associated with increased blood pressure risks, according to some official patient information.


Q: Why is Zyvoxid sometimes reserved for specific infections?

Linezolid is often reserved for treating serious infections caused by resistant bacteria to preserve its effectiveness. This approach is described as a measure intended to help preserve its effectiveness and discourage the further development of antibiotic resistance.


Q: Regarding the consumption of alcohol while taking Zyvoxid

Due to the drug’s MAO-inhibiting property, official patient information notes the potential for adverse effects from consuming alcoholic beverages that contain high levels of tyramine. Examples include draft beer and red wine, as their combination with the medicine may cause a significant elevation in blood pressure.


Q: Are there any specific supplements that interact with Zyvoxid?

Official documents caution that the MAO-inhibiting property means supplements containing high levels of tyramine or those intended to increase serotonin or adrenergic neurotransmitters should be used with caution. Examples may include L-tryptophan or St. John's Wort.


Q: Regarding the use of Zyvoxid during pregnancy

Regulatory information indicates that data on the use of Linezolid in pregnant women is limited. Because animal studies suggest a potential for reproductive toxicity, the drug is not generally recommended during pregnancy, and official guidance suggests it should only be used if the potential benefit is determined to outweigh the theoretical risk.


Q: What are the risks of taking Zyvoxid while breastfeeding?

Regulatory guidance suggests that Linezolid and its metabolites may pass into breast milk based on animal studies. Due to this potential exposure to the infant, official advice indicates that breastfeeding is not recommended throughout the period of treatment.


Q: Is Zyvoxid associated with any risk of vision problems?

Yes, Optic Neuropathy is documented as a serious safety concern in official documents. This condition can involve changes in vision like blurred vision or difficulty reading, and the risk is noted to increase when the drug is used for longer than the recommended 28-day period.


Q: What if I experience a rash while taking Zyvoxid?

A rash is a documented common adverse reaction, according to regulatory documents. Patients should be aware that severe skin conditions, such as Stevens-Johnson Syndrome, are also reported rarely. Official guidance notes the importance of observation for signs of an allergic or severe skin reaction if a rash develops.


Q: What are the known drug-drug interactions with Zyvoxid?

Linezolid is formally contraindicated with non-selective MAO Inhibitors and must not be used concurrently. There is also a risk of interaction with Serotonergic Agents (like some antidepressants), Adrenergic Agents (like decongestants), and drugs such as Carbamazepine and Rifampicin.


Q: What is the risk of resistance to Zyvoxid?

The development of bacterial resistance to Linezolid has been documented during its clinical use. Regulatory guidance suggests that, to help limit resistance, the drug should be reserved for use against infections that are known or strongly suspected to be caused by susceptible bacteria.


Q: Can Zyvoxid make you tired or drowsy?

The official side effect profile lists Dizziness as a common reaction. While tiredness or drowsiness are not explicitly listed in the most common categories, these symptoms may be associated with other documented side effects, such as anemia.


Q: Is Zyvoxid a broad-spectrum antibiotic?

Linezolid is generally regarded as having a relatively narrow spectrum of activity, as it is primarily directed against aerobic Gram-positive bacteria. Regulatory guidance often recommends reserving its use for those specific organisms.


Q: What are the signs of an allergic reaction to Zyvoxid?

Official regulatory materials list symptoms of a serious allergic reaction, which can include rash, difficulty breathing, or swelling of the face, tongue, or throat. Official documents note that hypersensitivity (an allergic reaction) to Linezolid is listed as an absolute contraindication for its use.


Q: Does Zyvoxid affect my blood sugar levels?

Yes, official warnings mention that Linezolid has been reported to cause hypoglycemia (low blood sugar). This effect is observed mainly in patients who are also taking insulin or other medicines used to lower glucose.


Q: Can Zyvoxid be used for long-term treatment?

The maximum licensed duration of treatment, according to official documents, is 28 days. The safety and efficacy of treatment courses extending beyond this period have not been established in controlled trials, and the risk of serious side effects increases with longer use.


Q: Is Zyvoxid approved by the FDA?

Yes, Linezolid (marketed as Zyvox in the U.S.) was approved by the U.S. Food and Drug Administration (FDA) in 2000 for its specific therapeutic indications, and its use remains governed by FDA prescribing information.


Q: Why do official documents note the need for dietary caution with Zyvoxid

Official documents note the need for dietary caution because Linezolid is a reversible Monoamine Oxidase Inhibitor (MAOI). When it is taken with certain foods high in tyramine, this MAOI activity can potentially cause a significant increase in blood pressure, known as a Hypertensive Crisis.

How should Zyvoxid be stored and disposed of?

How to Store and Dispose of Zyvoxid (Linezolid)

The storage and disposal of Zyvoxid must strictly adhere to officially documented regulatory requirements to maintain product stability and ensure environmental safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature, 20^circC to 25^circC (68^circF to 77^circF).
Protection Keep in the original container to protect from light and moisture; the infusion solution must not be frozen.
Handling The oral suspension must be used within 21 days after reconstitution and the bottle kept tightly closed.

Disposal Instructions

Zyvoxid must be kept out of the sight and reach of children.

Expired or unused medicine must not be discarded via wastewater or regular household waste. Disposal must be carried out in accordance with local requirements for pharmaceutical waste, as directed by national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zyvoxid found in:

A-Z Index: